Eye Diseases Clinical Trial
Official title:
Evaluation and Treatment Protocol for Potential Research Participants With Ocular Diseases
This study will evaluate and provide standard treatments for people with various eye
conditions. It will provide a resource for enrollment into new research protocols throughout
the Eye Institute and will allow institute specialists the opportunity to maintain their
expertise and gain additional knowledge of the course of various eye disorders. The
information obtained will allow for the evaluation of standard treatments and may lead to
ideas for future research.
People with diagnosed or undiagnosed eye disease and first-degree relatives of people with a
genetic or developmental eye disease may be eligible for this study. Participants are
evaluated and treated in the National Eye Institute. Blood or other tissue samples (e.g.,
urine, stool, hair, saliva or cheek swab) may be collected for future laboratory studies.
The National Eye Institute (NEI) is conducting a study to evaluate and provide standard
treatment to participants with various diagnosed and undiagnosed ocular conditions.
Objectives: The primary objective of this protocol is to provide a reservoir of patients for
enrollment into new research protocols throughout the NEI laboratories. Evaluating and
treating participants will allow the NEI specialists to maintain their expertise and gain
additional knowledge of the course of various eye disorders. The information obtained will
allow for the evaluation of standard treatments of the studied eye diseases. This
understanding may lead to ideas for future protocols. In some cases, blood or other biologic
samples (including tear fluid, urine, saliva, hair, stool or a cheek swab) will be obtained
for future laboratory studies.
Study Population: The number of participants to be enrolled has no logical upper limit, but
will be set to 5,000 patients with ocular diseases and their unaffected first-degree
relatives.
Design: This is an observational natural history study of multiple ocular diseases and their
progression and physiology.
Outcome Measures: No formal outcomes will be measured; however the clinical assessments of
enrolled participants can be used to measure the response to standard treatment. In addition,
DNA samples obtained may be used to identify and verify causative mutations, which may help
establish pathogenic mechanisms and genotype-phenotype correlations.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
| Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
| Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
| Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
| Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
| Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
| Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
| Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
| Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
| Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
| Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|